December 23, 2021, 06.09 PM
FILE - This undated image provided by Pfizer in November 2021 shows the company's Covid-19 pills. On Tuesday, Dec. 14, 2021, Pfizer said that its experimental Covid-19 pill is effective against the omicron variant and maintained its promising early performance against the virus in final testing. (Pfizer via AP, File) AP PHOTO/PFIZERFILE - This undated image provided by Pfizer in November 2021 shows the company's Covid-19 pills. On Tuesday, Dec. 14, 2021, Pfizer said that its experimental Covid-19 pill is effective against the omicron variant and maintained its promising early performance against the virus in final testing. (Pfizer via AP, File)


KOMPAS.com - US drug regulators approved Pfizer’s pill for treating Covid-19 on Wednesday, Dec. 22.

A pill to treat the deadly coronavirus marks a breakthrough as the pandemic enters its third year.

The US Food and Drug Administration's (FDA) authorization paves the way for another significant tool in the fight against the omicron variant. The EU had already previously approved the pill.

US President Joe Biden said the pill was a “significant step forward” on the path towards ending the pandemic, and his administration would work towards ensuring equitable distribution. He also said a law would be invoked to ensure Pfizer could ramp up production.

Also read: Pfizer Deal Authorizes Generic Pharmaceuticals to Produce Covid-19 Antiviral Pill

Pfizer’s clinical trial showed the antiviral pill was 90 percent effective in preventing extreme sickness requiring hospitalization and potential death in patients where there is a grave risk of severe illness.

Recent lab results suggest it is effective against the fast-spreading omicron variant.

What did the US regulator say?

The US authorized the Pfizer pill for treating mild-to-moderate Covid-19 in adults and children 12 years of age and older who weigh a minimum of 40 kilos (88 pounds) and are at high risk of developing severe symptoms of the disease.

In a statement, Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said, “This authorization provides a new tool to combat Covid-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe Covid-19.”

Page:


Comment wisely and responsibly. Comments are entirely the responsibility of the commentator as regulated in the ITE Law
Report
Thank You! We have received your report. We will remove comments that conflict with the Community Guidelines and the ITE Law.

More Headlines

News
January 14, 2022, 04.16 PM

Two-Headed Baby Born in Indonesia’s Sumatera

Close Ads X